Skip to main content

Viracor Eurofins 'Viracor TRAC'

Viracor Eurofins has begun offering its Viracor TRAC donor-derived, cell-free DNA assay for diagnosing kidney transplant rejection. The noninvasive liquid biopsy test has similar characteristics to other donor-derived cfDNA assays on the market, Viracor Eurofins said. Two ongoing prospective and one retrospective clinical trials are underway to further develop clinical data to support use of the test. The current gold standard for diagnosing kidney transplant rejection and surveillance is organ biopsy, which is both expensive and can lead to multiple complications for the patient, the firm noted.